Should high hTG levels in the absence of iodine uptake be treated: Against

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 30, Issue 1, 2003, Pages 160-163

  Biermann, M ^a   Schober, O ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131; THYROGLOBULIN; THYROTROPIN;

BONE METASTASIS; CANCER SURVIVAL; DRUG RESPONSE; DRUG UPTAKE; HUMAN; LUNG METASTASIS; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVIEW; SURVIVAL RATE; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA;

COMBINED MODALITY THERAPY; FALSE NEGATIVE REACTIONS; IODINE RADIOISOTOPES; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; THYROGLOBULIN; THYROID NEOPLASMS; THYROIDECTOMY; WHOLE-BODY COUNTING; WITHHOLDING TREATMENT;

EID: 0037565110     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-002-1004-1     Document Type: Review

References (15)

1. Mazzaferri EL. Treating high thyroglobulin with radioiodine: a magic bullet or a shot in the dark [editorial]? J Endocrinol Metab 1995; 80:1485-1487.
2. Pacini F, Lippi F, Formica N, Elisei R, Anelli S, Ceccarelli C, Pinchera A. Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. J Nucl Med 1987; 28:1888-1891.
3. Pineda JD, Lee T, Ain K, Reynolds JC, Robbins J. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Endocrinol Metab 1995; 80:1488-1492.
4. Schlumberger M, Challeton C, De Vathaire F, Travagli JP, Gardet P, Lumbroso JD, Francese C, Fontaine F. Radioactive iodine treatment and external radiotherapy for lung and bone metastases of differentiated thyroid carcinoma. J Nucl Med 1996; 37:598-605.
5. Casara D, Rubello D, Saladini G, Masarotto G, Favero A, Girelli ME, Busnardo B. Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables. J Nucl Med 1993; 34:1626-1631.
6. Altenvoerde G, Lerch H, Kuwert T, Matheja P, Schafers M, Schober O. Positron emission tomography with F-18-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels, and negative iodine scans. Langenbecks Arch Surg 1998; 383:160-163.
7. 131I-negative papillary thyroid carcinoma. J Nucl Med 2000; 41:1010-1015.
8. Simon D, Koehrle J, Reiners C, Boerner AR, Schmutzler C, Mainz K, Goretzki PE, Roeher HD. Redifferentiation therapy with retinoids: therapeutic option for advanced follicular and papillary thyroid carcinoma. World J Surg 1998; 22:569-574.
9. Grünwald F, Menzel C, Bender H, Palmedo H, Otte R, Fimmers R, Risse J, Biersack HJ. Redifferentiation therapy-induced radioiodine uptake in thyroid cancer. J Nucl Med 1998; 39:1903-1906.
10. Matthies A, Klemm E, Palmedo H, Reinhardt M, Grünwald F, Ezzidin S, Biersack H-J. Isotretinoin in der Behandlung des metastasierenden Schilddrüsenkarzinoms. Abstractband der 40 Jahrestagung der Deutschen Gesellschaft für Nuklearmedizin. Berlin: Blackwell; 2002:62.
11. Börner AR, Petrich T, Weckesser E, Fricke H, Hofmann M, Otto D, Weckesser M, Langen KJ, Knapp WH. Monitoring isotretinoin therapy in thyroid cancer using F18-FDG PET. Eur J Nucl Med 2002; 29:231-236.
12. Mazzaferri EL, Kloos RT. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Endocrinol Metab 2001; 86:1447-1463.
13. Dottorini ME, Vignati A, Mazzucchelli L, Lomuscio G, Colombo L. Differentiated thyroid carcinoma in children and adolescents: a 37-year experience in 85 patients. J Nucl Med 1997; 38:669-675.
14. Biko J, Demidchik YE, Reiners C. Spontanverlauf des pulmonal metastasierten kindlichen Schilddrüsenkarzinoms nach nicht vollständiger Elimination der Metastasen durch die hochdosierte Radiojodtherapie. Abstractband der 40 Jahrestagung der Deutschen Geselischaft für Nuklearmedizin. Berlin: Blackwell; 2002:62.
15. MSDS study group. Multicentric Study Differentiated Thyroid Carcinoma (MSDS): a prospective randomized trial on the benefits of percutaneous radiotherapy for differentiated thyroid carcinoma (DTC) pT4 pN0/1/x M0 R0-1. http://msds-studie.uni-muenster.de, 2002.